Asset Details
Do you wish to reserve the book?
Impact of Disease Severity and Disease-Modifying Therapies on Myostatin Levels in SMA Patients
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Impact of Disease Severity and Disease-Modifying Therapies on Myostatin Levels in SMA Patients
Do you wish to request the book?
Impact of Disease Severity and Disease-Modifying Therapies on Myostatin Levels in SMA Patients
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Impact of Disease Severity and Disease-Modifying Therapies on Myostatin Levels in SMA Patients
2024
Overview
Clinical trials with treatments inhibiting myostatin pathways to increase muscle mass are currently ongoing in spinal muscular atrophy. Given evidence of potential myostatin pathway downregulation in Spinal Muscular Atrophy (SMA), restoring sufficient myostatin levels using disease-modifying treatments (DMTs) might arguably be necessary prior to considering myostatin inhibitors as an add-on treatment. This retrospective study assessed pre-treatment myostatin and follistatin levels’ correlation with disease severity and explored their alteration by disease-modifying treatment in SMA. We retrospectively collected clinical characteristics, motor scores, and mysotatin and follistatin levels between 2018 and 2020 in 25 Belgian patients with SMA (SMA1 (n = 13), SMA2 (n = 6), SMA 3 (n = 6)) and treated by nusinersen. Data were collected prior to treatment and after 2, 6, 10, 18, and 30 months of treatment. Myostatin levels correlated with patients’ age, weight, SMA type, and motor function before treatment initiation. After treatment, we observed correlations between myostatin levels and some motor function scores (i.e., MFM32, HFMSE, 6MWT), but no major effect of nusinersen on myostatin or follistatin levels over time. In conclusion, further research is needed to determine if DMTs can impact myostatin and follistatin levels in SMA, and how this could potentially influence patient selection for ongoing myostatin inhibitor trials.
Publisher
MDPI AG,Multidisciplinary Digital Publishing Institute (MDPI),MDPI
Subject
/ Child
/ Computer Science Applications
/ Disease
/ Female
/ FSTN
/ GDF8
/ Humans
/ Infant
/ Male
/ Muscular Atrophy, Spinal - drug therapy
/ Muscular Atrophy, Spinal - metabolism
/ Myostatin - antagonists & inhibitors
/ Oligonucleotides - therapeutic use
/ Patients
/ Physical and Theoretical Chemistry
/ Proteins
